US 12,331,081 B2
Capsid variants and methods of using the same
Ina Chen, Sommerville, MA (US); Jeff Gerold, Cambridge, MA (US); Jerrah Holth, Sudbury, MA (US); Sylvain Lapan, Brookline, MA (US); Kathy S. Lin, Sommerville, MA (US); and Samuel Wolock, Cambridge, MA (US)
Assigned to DYNO THERAPEUTICS, INC., Watertown, MA (US)
Filed by DYNO THERAPEUTICS, INC., Watertown, MA (US)
Filed on Jul. 30, 2024, as Appl. No. 18/788,938.
Application 18/788,938 is a continuation of application No. 18/323,135, filed on May 24, 2023, granted, now 12,116,385.
Application 18/323,135 is a continuation of application No. PCT/US2022/077804, filed on Oct. 7, 2022.
Claims priority of provisional application 63/262,341, filed on Oct. 10, 2021.
Claims priority of provisional application 63/262,330, filed on Oct. 8, 2021.
Prior Publication US 2024/0417430 A1, Dec. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 7/00 (2006.01); A61K 48/00 (2006.01); C07K 14/015 (2006.01); C12N 15/86 (2006.01)
CPC C07K 14/015 (2013.01) [A61K 48/0058 (2013.01); C12N 15/86 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A variant adeno-associated virus (AAV) capsid polypeptide having at least 95% sequence identity to SEQ ID NO: 2 and comprising:
(a) a leucine at a position corresponding to V596 as compared to SEQ ID NO: 1;
(b) a serine at a position corresponding to N598 as compared to SEQ ID NO: 1; and
(c) an alanine at a position corresponding to I601 as compared to SEQ ID NO: 1.